HANDOK Inc.
Financials
Valuation Metrics
HANDOK Inc.'s Market Cap is ₩1181B. At end of 2025 it was ₩1542B. Ranked #1178 of 2,421 in KR market (top 49%), #549 of 781 on KOSPI (top 70%), #136 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 118.09B KRW | KR#1,178/2,421 Sec#136/231 |
| Revenue | 560.89B KRW | KR#583/2,421 Sec#29/231 |
| Net Income | -9.45B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 779.69B KRW | KR#563/2,421 Sec#31/231 |
| Net Assets | 255.08B KRW | KR#815/2,421 Sec#53/231 |
| Employees | 988 | KR#259/2,421 Sec#19/231 |
| Value | ||
| P/B | 0.46x | KR#717/2,421 Sec#31/231 |
| P/S | 0.21x | KR#386/2,421 Sec#8/231 |
| EV/EBITDA | 56.95x | KR#1,381/2,421 Sec#90/231 |
| FCF Yield | -8.37% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -3.71% | KR#1,742/2,421 Sec#123/231 |
| ROA | -1.21% | KR#1,697/2,421 Sec#120/231 |
| Op. Margin | 1.47% | KR#1,452/2,421 Sec#102/231 |
| Revenue Growth | 12.01% | KR#806/2,421 Sec#80/231 |
| Financial Health | ||
| Debt Ratio | 205.66% | KR#2,120/2,421 Sec#220/231 |
| Total Debt | 375.23B KRW | KR#357/2,421 Sec#16/231 |
| FCF | -9.88B KRW | KR#1,704/2,421 Sec#147/231 |
| Cash | 23.30B KRW | KR#1,157/2,421 Sec#79/231 |
| Current Ratio | 0.86x | KR#1,875/2,421 Sec#183/231 |
| Net Debt/EBITDA | 42.64x | KR#1,471/2,421 Sec#102/231 |
| Dividend | ||
| Div. Yield | 2.33% | KR#797/2,421 Sec#41/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -26.35% | KR#1,444/2,421 Sec#106/231 |
| 1M Return | -7.64% | KR#1,978/2,421 Sec#161/231 |
| From 52W High | -31.30% | KR#573/2,421 Sec#34/231 |
| 1Y MDD | -44.49% | KR#750/2,421 Sec#58/231 |
| Trading | ||
| Volume | 6,942 shares | KR#2,038/2,421 Sec#194/231 |
| Trading Value | 58.9M KRW | KR#1,779/2,421 Sec#182/231 |
| Foreign Own. | 2.18% | KR#1,569/2,421 Sec#148/231 |
| Per Share | ||
| EPS | -687 KRW | KR—/2,421 Sec—/231 |
| BPS | 18,533 KRW | KR#565/2,421 Sec#38/231 |
Company Info
Handok, a pharmaceutical company established in 1954 and listed on the securities market in 1976, transferred its healthcare product business division to Handok Healthcare Co., Ltd. It manufactures and sells professional and general medicines, including diabetes treatments like Amaryl, Tenelia, and Lantus, and hypertension treatments such as Aprovasc, Aprovel, and Coaprovel. The company also engages in medical device and diagnostic reagent sales, pharmaceutical contract manufacturing and quality control services, and real estate leasing. Handok is headquartered in Gangnam-gu, Seoul Metropolitan City.